June 2015
Volume 56, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2015
Molecular mechanism of dasatinib inhibition of matrix contraction
Author Affiliations & Notes
  • Rintaro Tsukahara
    Ophthalmology and Visual Sciences, University of Louisville, Louisville, KY
    Ophthalmology, Tokyo Medical University, Tokyo, Japan
  • Kevin McDonald
    Ophthalmology and Visual Sciences, University of Louisville, Louisville, KY
  • Hiroshi Goto
    Ophthalmology, Tokyo Medical University, Tokyo, Japan
  • Henry J Kaplan
    Ophthalmology and Visual Sciences, University of Louisville, Louisville, KY
  • Shigeo Tamiya
    Ophthalmology and Visual Sciences, University of Louisville, Louisville, KY
    Biochemistry and Molecular Biology, University of Louisville, Louisville, KY
  • Footnotes
    Commercial Relationships Rintaro Tsukahara, None; Kevin McDonald, None; Hiroshi Goto, None; Henry Kaplan, None; Shigeo Tamiya, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 410. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Rintaro Tsukahara, Kevin McDonald, Hiroshi Goto, Henry J Kaplan, Shigeo Tamiya; Molecular mechanism of dasatinib inhibition of matrix contraction. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):410.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: Traction retinal detachment (TRD) is the major complication of proliferative vitreoretinopathy (PVR) that is caused by contraction of epiretinal membranes, derived from retinal pigment epithelial (RPE) and Müller cells.We have previously reported that dasatinib, a FDA-approved tyrosine kinase inhibitor, can inhibit matrix contraction by both cell types without detectable toxicity. In this study, we examined the mechanism of dasatinib inhibition of matrix contraction caused by Muller cells.

Methods: Müller cells were isolated from porcine eyes using a papain/DNase kit, and used between passages 3-6. Type I collagen matrix contraction assays were used to examine the effect of drugs on contraction. Fluophore-conjugated phalloidin was used for the detection of actin cytoskeleton in these cells. Western-blot analyses were carried out to examine protein expression and phosphorylation status.

Results: As previously reported, dasatinib significantly inhibited matrix contraction by Müller cells. Dasatinib treatment led to decreased cell spreading and reduction of actomyosin stress fibers. Concomitantly, dasatinib-treated Müller cells had reduced phosphorylation of Src family kinase, paxillin, as well as myosin II light chain. Specific inhibitors of Rho/ROCK and myosin II confirmed the critical role played by this pathway on Müller cell contraction.

Conclusions: Our data demonstrate that dasatinib inhibits matrix contraction by Müller cells via interference with focal adhesion, as well as actomyosin contraction.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×